---
title: "extraintestinal manifestations of inflammatory bowel disease"
slug: "extraintestinal-manifestations-of-inflammatory-bowel-disease"
date: "2023-08-10"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[inflammatory bowel disease]]

# extraintestinal manifestations of inflammatory bowel disease

<table role="presentation"><thead><tr><th align="" xt-marked="ok">CATEGORY</th><th align="" xt-marked="ok">CLINICAL COURSE</th><th align="" xt-marked="ok">TREATMENT</th></tr></thead><tbody><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink" xt-marked="ok">Rheumatologic disorders (5â€“20%)</strong></td></tr><tr><td align="" xt-marked="ok">Peripheral arthritis</td><td align=""><p xt-marked="ok">Asymmetric, migratory</p><p xt-marked="ok">Parallels bowel activity</p></td><td align="" xt-marked="ok">Reduce bowel inflammation</td></tr><tr><td align="" xt-marked="ok">Sacroiliitis</td><td align=""><p xt-marked="ok">Symmetric: spine and hip joints</p><p xt-marked="ok">Independent of bowel activity</p></td><td align="" xt-marked="ok">Steroids, injections, methotrexate, anti-TNF</td></tr><tr><td align="" xt-marked="ok">Ankylosing spondylitis</td><td align=""><p xt-marked="ok">Gradual fusion of spine</p><p xt-marked="ok">Independent of bowel activity</p><p xt-marked="ok">Two-thirds have HLA-B27 antigen</p></td><td align="" xt-marked="ok">Physical therapy, steroids, injections, methotrexate, anti-TNF, IL-17 inhibitors, tofacitinib</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink" xt-marked="ok">Metabolic bone disorders (up to 40% of patients)</strong></td></tr><tr><td align="" xt-marked="ok">Osteoporosis</td><td align=""><p xt-marked="ok">Risk increased by glucocorticoids, cyclosporine, methotrexate, total parenteral nutrition, malabsorption, and inflammation</p><p xt-marked="ok">Fracture rates highest in the elderly (age &gt;60)</p></td><td align="" xt-marked="ok">Screening with DEXA scan, check vitamin D levels, treat if osteoporosis or osteopenia on long-term corticosteroids</td></tr><tr><td align="" xt-marked="ok">Osteonecrosis</td><td align="" xt-marked="ok">Death of osteocytes and adipocytes and eventual bone collapse; affects hips more than knees or shoulders; risk factor is steroid use</td><td align="" xt-marked="ok">Pain control, injections, joint replacement</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink" xt-marked="ok">Dermatologic disorders (10â€“20%)</strong></td></tr><tr><td align="" xt-marked="ok">Erythema nodosum</td><td align=""><p xt-marked="ok">Hot, red, tender, nodules/extremities</p><p xt-marked="ok">Parallels bowel activity</p></td><td align="" xt-marked="ok">Reduce bowel inflammation</td></tr><tr><td align="" xt-marked="ok">Pyoderma gangrenosum</td><td align=""><p xt-marked="ok">Ulcerating, necrotic lesions on extremities, trunk, face, stoma</p><p xt-marked="ok">Independent of bowel activity</p></td><td align="" xt-marked="ok">Antibiotics, steroids, cyclosporine, infliximab, dapsone, azathioprine, intralesional steroids; not debridement or colectomy</td></tr><tr><td align="" xt-marked="ok">Psoriasis</td><td align="" xt-marked="ok">Unrelated to bowel activity</td><td align="" xt-marked="ok">Topical steroids, light therapy, methotrexate, infliximab, adalimumab, ustekinumab</td></tr><tr><td align="" xt-marked="ok">Pyoderma vegetans</td><td align=""><p xt-marked="ok">Intertriginous areas</p><p xt-marked="ok">Parallels bowel activity</p></td><td align="" xt-marked="ok">Evanescent; resolves without progression</td></tr><tr><td align="" xt-marked="ok">Pyostomatitis vegetans</td><td align=""><p xt-marked="ok">Mucous membranes</p><p xt-marked="ok">Parallels bowel activity</p></td><td align="" xt-marked="ok">Evanescent; resolves without progression</td></tr><tr><td align="" xt-marked="ok">Metastatic Crohnâ€™s disease (CD)</td><td align=""><p xt-marked="ok">CD of the skin</p><p xt-marked="ok">Parallels bowel activity</p></td><td align="" xt-marked="ok">Reduce bowel inflammation</td></tr><tr><td align="">Sweet syndrome</td><td align=""><p>Neutrophilic dermatosis</p><p>Parallels bowel activity</p></td><td align="">Reduce bowel inflammation</td></tr><tr><td align="">Aphthous stomatitis</td><td align=""><p>Oral ulcerations</p><p>Parallels bowel activity</p></td><td align="">Reduce bowel inflammation/topical therapy</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink">Ocular disorders (1â€“11%)</strong></td></tr><tr><td align="">Uveitis</td><td align=""><p>Ocular pain, photophobia, blurred vision, headache</p><p>Independent of bowel activity</p></td><td align="">Topical or systemic steroids</td></tr><tr><td align="">Episcleritis</td><td align=""><p>Mild ocular burning</p><p>Parallels bowel activity</p></td><td align="">Topical corticosteroids</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink">Hepatobiliary disorders (10â€“35%)</strong></td></tr><tr><td align="">Fatty liver</td><td align="">Secondary to chronic illness, malnutrition, steroid therapy</td><td align="">Improve nutrition, reduce steroids</td></tr><tr><td align="">Cholelithiasis</td><td align=""><p>Patients with ileitis or ileal resection</p><p>Malabsorption of bile acids, depletion of bile salt pool, secretion of lithogenic bile</p></td><td align="">Reduce bowel inflammation; cholecystectomy in symptomatic patients</td></tr><tr><td align="">Primary sclerosing cholangitis (PSC)</td><td align=""><p>Intrahepatic and extrahepatic</p><p>Inflammation and fibrosis leading to biliary cirrhosis and hepatic failure</p><p>7â€“10% cholangiocarcinoma</p><p>Small-duct PSC involves small-caliber bile ducts and has a better prognosis</p></td><td align="">ERCP/high-dose ursodiol lowers risk of colonic neoplasia; cholecystectomy in patients with gallbladder polyps due to the high incidence of malignancy</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink">Urologic</strong></td></tr><tr><td align="">Nephrolithiasis (10â€“20%)</td><td align="">CD patients following small-bowel resection; calcium oxalate stones most common</td><td align="">Low-oxalate diet; control of bowel inflammation; surgical intervention</td></tr><tr><td colspan="3" align=""><strong xmlns:xlink="http://www.w3.org/1999/xlink">Less common extraintestinal manifestations</strong></td></tr><tr><td align="">Thromboembolic disorders</td><td align="">Increased risk of venous and arterial thrombosis; factors responsible include abnormalities of the platelet-endothelial interaction, hyperhomocysteinemia, alterations in the coagulation cascade, impaired fibrinolysis, involvement of tissue factorâ€“bearing microvesicles, disruption of the normal coagulation system by autoantibodies, and a genetic predisposition</td><td align="">Anticoagulation; control of inflammation</td></tr><tr><td align="">Cardiopulmonary</td><td align="">Endocarditis, myocarditis, pleuropericarditis, interstitial lung disease</td><td align="">Treatment is varied; stop 5-ASA agents as they can rarely cause interstitial lung disease</td></tr><tr><td align="">Systemic amyloidosis</td><td align="">Secondary (reactive) in long-standing IBD, especially CD</td><td align="">Colchicine</td></tr><tr><td align="">Pancreatitis</td><td align="">Duodenal fistulas, ampullary CD, gallstones, PSC, drugs (MP, azathioprine, 5-ASAs), autoimmune, primary CD of the pancreas</td><td align="">Treatment is varied; stop offending medication; diagnose and treat with ERCP and/or cholecystectomy</td></tr></tbody></table>
